Top Story

Bimatoprost Sustained-Release application acceptance tops weekly news highlights

July 21, 2019
In the Journals

Higher cholesterol levels associated with greater risk for primary open-angle glaucoma

July 18, 2019
Patients with higher levels of cholesterol are more at risk for primary open-angle glaucoma, while those who take statins to control cholesterol levels are at less risk…

Nicox completes enrollment in NCX 470 trial

July 18, 2019
Enrollment is complete in a phase 2 clinical trial of NCX 470, Nicox’s second-generation nitric oxide-donating bimatoprost analog, for the lowering of IOP in…

FDA accepts application for Bimatoprost Sustained-Release

July 17, 2019
The FDA has accepted a new drug application for Bimatoprost Sustained-Release to reduce IOP in primary open-angle glaucoma or ocular hypertension, Allergan announced…
More Headlines »
Clinical Science

Glaucoma Filtration Surgery Following Sustained Elevation of Intraocular Pressure Secondary to Intravitreal Anti-VEGF Injections

Ophthalmic Surgery, Lasers and Imaging Retina, July 2012, Volume 43 Issue 4
To document cases of sustained elevation of intraocular pressure (IOP) while receiving intravitreal anti-vascular…
More »

Neuroprotection in Glaucoma

This activity is supported by educational grants from Alcon Laboratories, Inc.; Bausch + Lomb; Glaukos Corporation; and Novartis Pharmaceuticals Corporation.

This educational activity will review the latest developments and concepts regarding neuroprotection in patients with…
More »
Meeting News

VIDEO: Device and technique updates in MIGS

June 21, 2019
More »